Matt Wiley

Mr. Wiley brings over 25 years of expertise in sales, marketing, and strategic leadership, with a proven track record in launching specialty pharmaceutical products. He joins Definium from BioXcel Therapeutics, where he served as CCO overseeing the launch of the company’s first acute treatment of agitation associated with schizophrenia and bipolar disorder. Prior to BioXcel, Mr. Wiley served as CCO at VYNE Therapeutics, overseeing all commercial objectives related to the launch of the company’s first two dermatology products. Before this, he served as Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals’ sleep medicine unit, where he led commercial strategies for the company’s treatments for narcolepsy and sleep apnea and developed the successful growth strategy for XYREM™ for narcolepsy, which achieved blockbuster status over his tenure. He also served as Vice President of Marketing at Azur Pharma, supporting the startup of U.S. operations and the company’s acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma. Mr. Wiley holds a Bachelor of Arts in English from Syracuse University, supplemented by executive coursework in Marketing and Finance at the University of Chicago Booth School of Business.